Medicines, Healthcare Products Regulatory Agency Authorises GlaxoSmithKline's Arexvy, First Respiratory Syncytial Virus Vaccine for Older Adults
July 11, 2023
July 11, 2023
LONDON, England, July 11 (TNSjou) -- GlaxoSmithKline, a biopharmaceutical company, issued the following news release on July 10, 2023:
* * *
- Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time
- In the UK, RSV leads to an estimated 14,000 hospitalisations and an estimated 8,000 deaths in adults 60 years of age and older each year
- The authorisation is based on phase III efficacy data . . .
* * *
- Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time
- In the UK, RSV leads to an estimated 14,000 hospitalisations and an estimated 8,000 deaths in adults 60 years of age and older each year
- The authorisation is based on phase III efficacy data . . .